Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
70 participants
INTERVENTIONAL
2023-08-07
2025-08-07
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Functional magnetic resonance imaging (MRI) is now able to provide T1 mapping sequence. In Fabry disease, T1 mapping is currently used to assess the degree of myocardial involvement. The MRI for assessement of Fabry Cardiomyopathy is now recommended by the 2022 national diagnostic and care protocol (PNDS) in France. However there is no data about T1 mapping values in kidney in Fabry's disease The main Objective is to describe renal performance through multi-parametric MRI in Fabry nephropathy and the primary outcome will be the quantification of renal T1 in Fabry patients.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Characterisation of Heart Involvement in Fabry Disease With T1 Mapping
NCT04708301
Study of the Prevalence of Fabry Disease in French Dialysis Patients
NCT02843334
Detection of Fabry Disease in Chronic Renal Failure Patients in Area Provence - Alpes - Côte d'Azur
NCT01374997
Epidemiological Study of Fabry Disease Screening in Chronic Kidney Disease Patients
NCT05056636
Biomarkers and Cardiac Imaging Diagnostic Assay for Monitoring Patients With Fabry Disease
NCT05698901
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Fabry disease
T1 mapping measurement
T1 mapping values to test the ability of the MRI sequence to detect Gb3 in kidney
Patients undergoing renal functional exploration
Patients undergoing renal functional exploration for a reason other than Fabry disease, amyloidosis, hemochromatosis
T1 mapping measurement
T1 mapping values to test the ability of the MRI sequence to detect Gb3 in kidney
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
T1 mapping measurement
T1 mapping values to test the ability of the MRI sequence to detect Gb3 in kidney
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Adult patient
* Patient informed of the study and agree to participate
* Patient affiliated to a social security or beneficiaries of a similar scheme
Exclusion Criteria
* kidney transplant,
* polycystic kidney disease,
* Pregnant, parturient or breastfeeding
* Contraindications to MRI
* Subject participating in another research including an exclusion period still in progress at inclusion
* Persons deprived of their liberty by a judicial or administrative decision,
* Adults subject to a legal protection measure (safeguard measure, guardianship, curators)
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hospices Civils de Lyon
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hopital Femme Mère Enfant
Bron, , France
Hopital Edouard Herriot
Lyon, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2023-A00475-40
Identifier Type: OTHER
Identifier Source: secondary_id
69HCL22_0934
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.